Learn more about whether Alvotech or Vericel Corporation is a better investment based on AAII's A+ Investor grades, which ...

MediWound (NASDAQ:MDWD – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a report issued on Friday. Other research analysts have also issued reports about the company.

MediWound (NASDAQ:MDWD – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports.

Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcersExpanded strategic research collaborations with industry ...

Examination revealed edema of the left ear lobe. On the posterior surface there was a small ulcerated papule, covered by a dry black eschar and surrounded by an area of erythema. No adenopathy was ...

Vericel's niche in regenerative medicine is undervalued, with FDA-approved products like MACI, Epicel, and NexoBrid driving steady revenue growth and profitability. The company's strong financials ...